The cure rate of early cancer is much higher than that of the middle and late stages, and the side effects of treatment are limited.

The cure rate of early-detected cancer is over 90%, so it’s particularly important to do early cancer detection.

Alercell is an early-stage biopharmaceutical company developing novel therapeutics and oncology diagnostics tests with the core mission of developing and commercializing oncology diagnostic tests to improve diagnostic accuracy and diagnostic speed.

Alercell is also developing a neural interface to activate novel messaging to the DNA of patient with neurodegenerative diseases.

Alercell is proud to introduce two new tests that are both first of their genre.

  1. 1. LENA Q51® the first Leukemia Diagnostic Tests able to test up
  2.     51 genes mutations.

    2. LENA S1® the first lung cancer diagnostic test
         based on methylation.